Why the study?
Arrhythmias are common in continuous flow LVAD patients and carry significant morbidity and mortality, yet their management differs substantially from general heart failure patients and presents unique technical challenges.
This clinical consensus statement outlines specific strategies and challenges for managing arrhythmias in LVAD patients using anti-arrhythmic drugs and catheter ablation.
Answers are grounded in this paper and cite their sources.
Guides arrhythmia management in LVAD patients; extends consensus strategies to a high-prevalence population with limited prior standardization.
Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common with a prevalence of 20-50% at one year after LVAD implantation. Arrhythmias predispose these patients to additional risk and are associated with considerable morbidity from recurrent implantable cardioverter-defibrillator shocks, progressive failure of the unsupported right ventricle, and herald an increased risk of mortality. Management of patients with arrhythmias and LVAD differs in many aspects from the general population heart failure patients. These include ruling out the reversible causes of arrhythmias that in LVAD patients may include mechanical irritation from the inflow cannula and suction events. For patients with symptomatic arrhythmias refractory to medical treatment, catheter ablation might be relevant. There are specific technical and procedural challenges perceived to be unique to LVAD-related ventricular tachycardia (VT) ablation such as vascular and LV access, signal filtering, catheter manoeuvrability within decompressed chambers, and electroanatomic mapping system interference. In some patients, the arrhythmogenic substrate might not be readily accessible by catheter ablation after LVAD implantation. In this regard, the peri-implantation period offers a unique opportunity to surgically address arrhythmogenic substrate and suppress future VT recurrences. This document aims to address specific aspects of the management of arrhythmias in LVAD patients focusing on anti-arrhythmic drug therapy and ablations.
No takes yet. Share an insight, caveat, or question.
Peichl et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: